Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis.

Daniel G K RasmussenMichael K HansenPeder FrederiksenYunyun LuoMartin PehrssonBruce C NealMorten A KarsdalFederica Genovese

Published in: Diabetes, obesity & metabolism (2024)

The changes in PRO-C3 and CTX-III reflect a shift in the dynamics of COL3 turnover following treatment with canagliflozin. These biomarkers are promising pharmacodynamic tools that can be used to monitor the impact of canagliflozin treatment and possibly other sodium-glucose co-transporter-2 inhibitors on tissue remodelling in future interventional trials.

Keyphrases

type iii
bone mineral density
quality improvement
escherichia coli
body composition
current status
postmenopausal women
tissue engineering